BSEM-004

**BSEM-004** is an investigational amniotic fluid matrix therapy from BioStem Technologies being explored for osteoarthritis. Publicly available information indicates it is a regenerative medicine product derived from perinatal tissue rather than a conventional small-molecule pharmaceutical, but detailed composition, manufacturing attributes, route of administration, and validated molecular mechanism of action have not been clearly disclosed in accessible primary sources. The program appears to have been presented by the company as a potential therapy for osteoarthritis, but there is little evidence of advanced clinical development and the asset has been listed in pipeline databases as having no clear ongoing development progress.

Other names

Amniotic Fluid Matrix